NOLA.com6d
Chronic lung disease rates increase in Louisiana, despite national rates remaining the same
In 2021,138,825 people died from COPD in the U.S., making it the sixth overall leading cause of death and the fifth ...
News Medical on MSN18h
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
healthday29m
Childhood Smoking Ups COPD Risk
Young teens might think smoking makes them look cool, but it’s likely to take their breath away in adulthood, a new st ...
EurekAlert!1d
Expanded research on COPD and metabolic syndrome would advance patient-centered care
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
Childhood smoking increases a person's risk of developing COPD
Childhood smoking before age 15 increases a person's risk of developing chronic obstructive pulmonary disease (COPD), ...
News Medical on MSN1d
Smoking before age 15 significantly increases risk of chronic lung disease
A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...
California wildfires: How smoke, poor air quality can impact health of people hundreds of miles from Los Angeles
Smoke from wildfires — like the ones in Los Angeles — can have health consequences. Here's what experts expect.
Pharmaceutical Technology10d
TRN-157 by Theron Pharmaceuticals for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
TRN-157 is under clinical development by Theron Pharmaceuticals and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).
Pharmaceutical Technology10d
AZD-6793 by AstraZeneca for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval
AZD-6793 is under clinical development by AstraZeneca and currently in Phase I for Chronic Obstructive Pulmonary Disease (COPD).